IceCure Medical Ltd publishes presentation on FDA authorized ProSense cryoablation device for minimally invasive breast cancer treatment
Reuters
Oct 09
IceCure Medical Ltd publishes presentation on FDA authorized ProSense cryoablation device for minimally invasive breast cancer treatment
IceCure Medical Ltd. has highlighted the recent U.S. FDA marketing authorization of its ProSense® system for the local treatment of early-stage low-risk breast cancer in women aged 70 and above, when used with adjuvant endocrine therapy. ProSense® is described as a minimally invasive cryoablation device utilizing advanced liquid nitrogen technology to freeze and destroy benign or cancerous tumors with minimal pain. The device is approved for use in multiple countries and has received recognition for its clinical impact. IceCure Medical notes the assignment of a CPT Category III code for breast cancer cryoablation, supporting reimbursement for eligible procedures. The company is also conducting a post-marketing study to collect additional data on the device's use. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on October 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.